The aim of this study is to investigate the effect of a single bout of NMES on muscle protein synthesis rates in healthy elderly males.
ID
Source
Brief title
Condition
- Other condition
- Protein and amino acid metabolism disorders NEC
- Muscle disorders
Synonym
Health condition
muscle metabolism
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Muscle protein synthesis rates, expressed as fractional synthetic rate (FSR).
Secondary outcome
Muscle tracer enrichment, digestion and absorption kinetics of a casein drink
influenced by NMES.
Background summary
With human aging there is a gradual but progressive decline in skeletal muscle
mass, termed sarcopenia.. While the underlying cause of sarcopenia is likely to
be multifaceted, a primary factor is that elderly individuals frequently
experience short periods of muscle disuse following limb immobilization or
bed-rest (due to injury or illness) causing rapid muscle loss. Elderly
individuals seem to be more susceptible to muscle disuse atrophy and are less
likely to fully regain their muscle tissue during subsequent rehabilitation
when compared to the young. Muscle loss during a period of disuse is attributed
to an impairment of muscle protein synthesis rates. Accordingly, feasible
strategies for maintaining muscle protein synthesis rates in elderly
individuals, and thus having the potential to attenuate the loss of muscle mass
during disuse need to be pursued. Local neuromuscular electrical stimulation
(NMES) offers such a potential strategy but, as yet, remains relatively
unexplored.
Study objective
The aim of this study is to investigate the effect of a single bout of NMES on
muscle protein synthesis rates in healthy elderly males.
Study design
10 healthy, elderly men will consume a 20g bolus of intrinsically
L[13C]phenylalanine labelled casein protein immediately following 70 min of
one-legged NMES. Regular blood samples will be collected and muscle biopsies
will be obtained immediately prior to protein ingestion and 240 min after
ingestion from both legs to determine de novo muscle protein synthesis rates
from both the stimulated (STIM) and un-stimulated control (CON) legs.
Intervention
Consumption of a 20g bolus of intrinsically L[13C]phenylalanine labelled casein
protein and 70 min of one-legged NMES.
Study burden and risks
The risks involved in participating in this experiment are minimal. Insertion
of the catheters in a vein is comparable to a normal blood draw and the only
risk is a small local hematoma. This is the same for the muscle biopsies. The
incision made for obtaining the muscle biopsy will be done by an experienced
physician, following local anesthetics of the skin and muscle fascia, and will
heal completely. The test beverages contain intrinsically labeled dietary
protein which is safe for human consumption and has been used in previous
studies (MEC 11-3-057 and MEC 11-3-088). NMES carries no potential risks other
than slight skin irritation from the surface electrodes.
Universiteitssingel 50 room 2.208
Maastricht 6229 ER
NL
Universiteitssingel 50 room 2.208
Maastricht 6229 ER
NL
Listed location countries
Age
Inclusion criteria
Male
Age 65 - 85 years
18.5 < BMI < 30 kg*m2
Exclusion criteria
- Type II diabetes
- All co morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthrosis, arthritis, spasticity/rigidity, all neurological disorders and paralysis).
- Use of anticoagulants, blood diseases, allergy for lidocain
- Use of NSAIDs and acetylsalicylic acid
- Patients suffering from PKU (Phenylketonuria)
- Presence of implantable cardioverter defibrillator and/or pacemaker
- Performed regular resistance type exercise in the past 6 months
- Use of any tools to assist during walking (cane/ crutches/ walker)
- (Partial) foot/ leg amputation
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
ClinicalTrials.gov | NCT01615276 |
CCMO | NL40564.068.12 |